Skip to main content
SpringerLink
Log in

ISA 247

trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524

  • Adis R & D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Isotechnika Inc. Isotechnika Earns Significant Drug Development Milestone Payment. Media Release: 26 Sep 2002. Available from URL: http://www.isotechnika.com

    Google Scholar 

  2. Isotechnika Inc, Roche Pharmaceutical Division. Isotechnika and Roche sign largest drug development agreement in Canadian history. Media Release: 9 Apr 2002. Available from URL: http://www.isotechnika.com

    Google Scholar 

  3. Isotechnika Inc. Isotechnika Signs Option Agreement for Topical Delivery Technology of ISA247. Media Release: 25 Apr 2006. Available from URL: http://www.isotechnika.com

    Google Scholar 

  4. Isotechnika Inc, Atrium Medical Corporation. Isotechnika and Atrium Medical Announce Licensing Agreement for Use of TAFA93 and ISA247 With Medical Devices. Media Release: 30 Sep 2005. Available from URL: http://www.isotechnika.com

    Google Scholar 

  5. Isotechnika Inc. Isotechnika signs agreement granting Lux Biosciences Worldwide Ophthalmic rights to ISA247. Media Release: 25 May 2006. Available from URL: http://www.isotechnika.com

    Google Scholar 

  6. Isotechnika Inc. Isotechnika Announces Interim Blinded Phase III Psoriasis Results. Media Release: 3 Aug 2005. Available from URL: http://www.isotechnika.com

    Google Scholar 

  7. Isotechnika Inc. Isotechnika Inc. announces highlights and financial results for first quarter of 2006. Media Release: 15 May 2006. Available from URL: http://www.isotechnika.com

    Google Scholar 

  8. Isotechnika Inc. Isotechnika Inc. Announces Fourth Quarter and Year End Financial Results. Media Release: 11 Mar 2003. Available from URL: http://www.isotechnika.com

    Google Scholar 

  9. Isotechnika Inc. Isotechnika and Roche Announce Completion of Patient Recruitment for ISA247 Phase II A Clinical Trial in Kidney Transplantation. Media Release: 3 Oct 2002. Available from URL: http://www.isotechnika.com

    Google Scholar 

  10. Isotechnika Inc. Isotechnika Inc. Achieves all Endpoints in Multiple Ascending Dose Study for ISA247. Media Release: 3 Nov 2004. Available from URL: http://www.isotechnika.com

    Google Scholar 

  11. Isotechnika Inc. Isotechnika Inc. Reports Interim Results of QTc Trial. Media Release: 9 Sep 2004. Available from URL: http://www.isotechnika.com

    Google Scholar 

  12. Isotechnika Inc. Positive Data From Trans-ISA247 Single Ascending Dose Trial. Media Release: 6 Jul 2004. Available from URL: http://www.isotechnika.com

    Google Scholar 

  13. Isotechnika Inc. FDA Agrees to Clinical Development Plans for ISA247. Media Release: 25 Feb 2004. Available from URL: http://www.isotechnika.com

    Google Scholar 

  14. Isotechnika Inc. Isotechnika Receives European Patent for Lead Immunosuppressive Drug, ISA247. Media Release: 3 Oct 2006. Available from URL: http://www.isotechnika.com

    Google Scholar 

  15. Isotechnika Inc. Isotechnika receives additional U.S. patent for lead immunosuppressive drug, ISA247 — 30 June 2006. Media Release: 30 Jun 2006. Available from URL: http://www.isotechnika.com

    Google Scholar 

  16. Isotechnika Inc. Isotechnika receives additional U.S. patent for lead immunosuppressive drug, ISA247. Media Release: 14 Feb 2006. Available from URL: http://www.isotechnika.com

    Google Scholar 

  17. Yatscoff RW, Abel MD, Aspeslet LJ, et al. ISA(TX)247: phase 1 clinical trial results of the novel calcineurin inhibitor. Journal of Rheumatology 28 (Suppl. 63): 109, Jul 2001

    Google Scholar 

  18. Wasel NR, Gupta A, Tomi Z, et al. Pharmacokinetics and pharmacodynamics of ISA247 in a phase III, randomized, multicenter, double-blind, placebo-controlled study. Journal of the American Academy of Dermatology 54 (Suppl. 1): AB9 (plus poster) abstr. P36, No. 3, Mar 2006

    Google Scholar 

  19. Yatscoff RW, Abel MD, Aspeslet LJ, et al. A novel calcineurin inhibitor with minimal renal toxicity: ISA(TX)247. Journal of Rheumatology 28 (Suppl. 63): 109, Jul 2001

    Google Scholar 

  20. Isotechnika Inc. Isotechnika Presents Interim Clinical Data at the International Congress of the Transplantation Society. Media Release: 29 Aug 2002. Available from URL: http://www.isotechnika.com

    Google Scholar 

  21. Yatscoff RW, Abel MD, Aspeslet LJ, et al. Phase 2, randomized, multicenter, open-label study of ISA247 and Neoral (Rm) in post-renal transplant patients. American Journal of Transplantation 3 (Suppl. 5): 463 (plus oral presentation) abstr. 1215, 2003

    Google Scholar 

  22. Papp K, Bissonnette R, Langley R, et al. A phase III randomized multicentre, double-blind, placebo-controlled study of ISA247 in plaque psoriasis patients: an interim report. 80th Annual Conference of the Canadian Dermatology Association: [1 page], 28 Jun 2005. Available from: URL: http://www.isotechnika.com

    Google Scholar 

  23. Isotechnika Inc. Isotechnika Inc. announces highlights and financial results for first quarter. Media Release: 13 May 2005. Available from URL: http://www.isotechnika.com

    Google Scholar 

  24. Papp K, Langley R, Bissonnette R, et al. A phase III, randomized, multicenter, double-blind, placebo-controlled study of ISA247 in plaque psoriasis patients. Journal of the American Academy of Dermatology 54 (Suppl. 1): AB9 (plus poster) abstr. P33, No. 3, Mar 2006

    Google Scholar 

  25. Isotechnika Inc. Isotechnika’s Phase III Psoriasis Trial Achieves Clinical Endpoints. Media Release: 21 Sep 2005. Available from URL: http://www.isotechnika.com

    Google Scholar 

  26. Isotechnika Inc. Isotechnika’s Phase III Psoriasis Spirit Trial Achieves Safety and Efficacy Endpoints. Media Release: 7 Nov 2005. Available from URL: http://www.isotechnika.com

    Google Scholar 

  27. Isotechnika Inc. Isotechnika Announces Nine Month Safety Data From the Phase III Psoriasis Trial for ISA247. Media Release: 8 Dec 2005. Available from URL: http://www.isotechnika.com

    Google Scholar 

  28. Isotechnika Inc. Isotechnika announces preliminary 48 week clinical data from the Phase III ISA247 psoriasis trial. Media Release: 20 Mar 2006. Available from URL: http://www.isotechnika.com

    Google Scholar 

  29. Gregory CR, Kyles AE, Bernsteen L, et al. Compared with cyclosporine, ISA(TX)247 significantly prolongs renal-allograft survival in a northern prmate model. Transplantation 78: 681–685, No. 5, 15 Sep 2004

    Article  PubMed  CAS  Google Scholar 

  30. Mayo P, Freitag D, Boutouyrie-Dumont B, et al. Pharmacokinetics and pharmacodynamics of ISA247 a new generation calcineurin inhibitor in stable renal transplant patients. American Journal of Transplantation 4 (Suppl. 8): 490, May 2004

    Google Scholar 

  31. Isotechnika Inc. Isotechnika to Present at International Dermatology Conference. Media Release: 3 Dec 2002. Available from URL: http://isotechnika.com

    Google Scholar 

  32. Isotechnika Inc. Isotechnika and Roche Announce Completion of Patient Recruitment for ISA(TX)247 Phase II Clinical Trial in Psoriasis. Media Release: 26 Jun 2002. Available from URL: http://www.isotechnika.com

    Google Scholar 

  33. Isotechnika Inc. Isotechnika’s Phase II Clinical Trial of ISA247 in Patients With Psoriasis Yields Impressive Results. Media Release: 10 Mar 2003. Available from URL: http://www.isotechnika.com

    Google Scholar 

  34. Lynde C, Kunynetz R, Guenther L, et al. A phase III, randomized, multicenter, double-blind, placebo-controlled, quality of life study of ISA247 in plaque psoriasis patients. Journal of the American Academy of Dermatology 54 (Suppl. 1): AB210 (plus poster) abstr. P2851, No. 3, Mar 2006

    Google Scholar 

  35. Isotechnika Inc. Isotechnika Announces Initial Data From Phase IIb Kidney Transplant Trial. Media Release: 16 Nov 2006. Available from URL: http://www.isotechnika.com

    Google Scholar 

  36. Isotechnika Inc. Isotechnika Releases Final Results of Phase IIa Kidney Transplant Trial at American Transplant Congress. Media Release: 4 Jun 2003. Available from URL: http://www.isotechnika.com

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

ISA 247. Drugs R D 8, 103–112 (2007). https://doi.org/10.2165/00126839-200708020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200708020-00005

Keywords

Search

Navigation